9,450 Shares in CVS Health Co. (NYSE:CVS) Acquired by Sava Infond d.o.o.

Sava Infond d.o.o. purchased a new stake in CVS Health Co. (NYSE:CVS) during the fourth quarter, Holdings Channel reports. The firm purchased 9,450 shares of the pharmacy operator’s stock, valued at approximately $424,000.

Several other hedge funds have also recently bought and sold shares of the stock. Larson Financial Group LLC raised its stake in shares of CVS Health by 258.9% in the third quarter. Larson Financial Group LLC now owns 3,542 shares of the pharmacy operator’s stock valued at $223,000 after acquiring an additional 2,555 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in CVS Health by 7.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,096,238 shares of the pharmacy operator’s stock valued at $68,931,000 after purchasing an additional 79,132 shares during the last quarter. Avestar Capital LLC acquired a new position in CVS Health in the third quarter worth $326,000. RPg Family Wealth Advisory LLC bought a new stake in shares of CVS Health during the third quarter worth $40,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of CVS Health by 3.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 261,194 shares of the pharmacy operator’s stock valued at $16,424,000 after buying an additional 9,418 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their position. The disclosure for this purchase can be found here. 0.24% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CVS. Barclays raised their price objective on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research report on Tuesday, December 3rd. Argus set a $77.00 target price on shares of CVS Health in a research report on Tuesday, February 18th. Finally, StockNews.com raised shares of CVS Health from a “sell” rating to a “hold” rating in a research note on Thursday, February 13th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.39.

CVS Health Price Performance

Shares of CVS opened at $67.59 on Friday. The stock has a 50 day simple moving average of $61.83 and a 200 day simple moving average of $57.60. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The firm has a market capitalization of $85.22 billion, a PE ratio of 18.47, a P/E/G ratio of 0.98 and a beta of 0.54.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Sell-side analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a $0.665 dividend. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.94%. CVS Health’s dividend payout ratio (DPR) is 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.